Program
Pneumococcal Conjugate Vaccine - formulation 1-SP0202-IIb
A development code. Also written as “Pneumococcal Conjugate Vaccine - formulation 2-SP0202-VI”, “Pneumococcal Conjugate Vaccine - formulation 3-SP0202-VII” and “Pneumococcal Conjugate Vaccine formulation 1”.
In Sanofi’s pipeline, 21-valent conjugate vaccine
. Its studies are mostly in Chickenpox, led by Sanofi.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofi | 20 open or running | phase 2since May 18, 2020 | May 18, 2020 | none ahead |
- Named in Sanofi’s own pipeline as
SP0202
, phase 3, as of Sep 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 18, 2020First study: phase 2 study in Pneumococcal ImmunisationFirst studyNCT04398706 · 852 enrolled · United States, Canada, Honduras and more
- Oct 5, 2020Phase 2 study in Pneumococcal ImmunizationNCT04583618 · 750 enrolled · United States
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“21-valent conjugate vaccine”the company's pipeline, read by Claude · source
“Pneumococcal Conjugate Vaccine - formulation 1-SP0202-IIb”name, read by Claude
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04583618Pneumococcal Immunization · United States | 2 | Completed | Aug 9, 2021 | 750 |
| NCT04398706Pneumococcal Immunisation · United States, Canada, Honduras and more | 2 | Completed | Aug 10, 2023 | 852 |
How it is read
Names in the registry
- “Pneumococcal Conjugate Vaccine - formulation 1-SP0202-IIb”, 1 entry
- “Pneumococcal Conjugate Vaccine - formulation 2-SP0202-VI”, 1 entry
- “Pneumococcal Conjugate Vaccine - formulation 3-SP0202-VII”, 1 entry
- “Pneumococcal Conjugate Vaccine formulation 1”, 1 entry
- “Pneumococcal Conjugate Vaccine formulation 2”, 1 entry
Codes read as this program: SP0202.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.